Procter & Gamble (PG)
NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-09-04
$146.44-0.33%
Close 2026-09-04 · 1-day change
NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-09-04
QuarterlyIQ Insights · PG
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $146 the market pays 21× p/e — above the 17× p/e peer median but in line with its own 22× history. That premium reflects a durable franchise our peer-anchored $118 fair value understates; treat the 'expensive vs peers' read with medium confidence. Analysts target $142–$156. Note: our $118 fair value sits below the entire analyst range ($142–$156). Even valued only for durable growth at sustainable margins, it's worth about $155 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $149.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $116.68 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $129.27 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $68.35 | — | — | TTM | high |
| graham number | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$142.00 – $156.00 (median $149.00) · 5 analysts · as of 2026-08-24
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price the business can't be justified by any reasonable horizon of the forecast growth; the price already runs past what the model can underwrite. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $6.36/sh owner earnings.
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $59.03 |
| — |
| — |
| TTM |
| high |
| Peer EV/EBITDA | 12M | $109.26 | 11.7 | 10.21 | TTM | high |
| Peer P/FCF | 12M | $104.78 | 15.9 | 6.59 | TTM | high |
| Peer P/E | 12M | $111.41 | 15.8 | 7.05 | ntm analyst | high |
| Peer P/S | 12M | $30.74 | 0.9 | 36.02 | TTM | high |
| PEG | 12M | $61.03 | 8.9 | 6.89 | TTM | high |
| residual income | 12M | $41.42 | — | — | TTM | high |
| Own P/E history | 12M | $148.53 | 21.6 | 6.89 | TTM | high |
| triangulated | 12M | $117.35 | 16.8 | 6.98 | Triangulated | high |
| Peer P/FCF | 3Y | $120.94 | 15.9 | 7.60 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $119.74 | 15.8 | 7.58 | Analyst | medium |
| Peer P/S | 3Y | $33.03 | 0.9 | 38.70 | guidance | medium |
| PEG | 3Y | $67.12 | 8.9 | 7.58 | Analyst | medium |
| Own P/E history | 3Y | $163.37 | 21.6 | 7.58 | Analyst | medium |
| Peer P/FCF | 5Y | $133.08 | 15.9 | 8.36 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $124.58 | 15.8 | 7.88 | Analyst | high |
| Peer P/S | 5Y | $34.37 | 0.9 | 40.27 | guidance | high |
| PEG | 5Y | $69.83 | 8.9 | 7.88 | Analyst | high |
| Own P/E history | 5Y | $169.97 | 21.6 | 7.88 | Analyst | high |